Our Grants
2024 TKF Grant Recipient
Dr. Eric Wang
The Jackson Laboratory for Genomic Medicine
Dr. Wang's exciting research into the RUNX1 gene and its isoforms aims to understand chemotherapy resistance, and therefore the potential for novel therapeutic strategies that increase the treatment's effectiveness.
2024 TKF Grant Recipient
Dr. Jae Park
Memorial Sloan Kettering Cancer Center
We are pleased to announce a new partnership with Memorial Sloan Kettering Cancer Center and our support of a first-of-its-kind CAR-T cell therapy clinical trial, led by Dr. Jae Park. Our philanthropic support will help this early Phase I trial reach more patients in need - with the ultimate goal of demonstrating favorable results along the path to FDA approval.
2023 TKF Grant Recipient
Dr. Theodoros Karantanos
Johns Hopkins University School of Medicine
Dr. Karantanos' research is related to the dissection of the molecular biology of CCRL2/STAT1 pathway in secondary acute myeloid leukemia.
2022 TKF Grant Recipient
Xufeng Chen, PhD
New York University School of Medicine
Dr. Chen’s research targets Antigen Presentation for Next-Generation Immunotherapy of Acute Myeloid Leukemia (AML). Our proposed studies will not only advance our knowledge of AML-associated regulation of antigen presentation but also provide new candidates for next-generation cancer immunotherapy, that may offer a better therapeutic option to patients with poor responses to current therapies.
2021 TKF Grant Recipient
Matt Christopher, MD, PhD
Washington University in St Louis
Dr. Christopher’s research will focus on a study of patients who relapsed after stem cell transplant. The study will aim to discover what mutations or other genetic changes might happen that allows the leukemia cells to relapse.
2020 TKF Grant Recipient
Bridget Marcellino, MD, PhD
Icahn School of Medicine at Mt. Sinai – New York, NY
Dr. Marcellino’s research is related to enhancing natural killer cell recognition of leukemic cells.
2020 TKF Grant Recipient
Dr. Mario A. BlancoIcahn
School of Medicine at Mt. Sinai – New York, NY
Dr. Blancolcahn’s research is related to an alternative type of AML therapy called “differentiation therapy” which aims to treat patients by changing their rapidly dividing cancer cells into cells that do not divide.
2019 TKF Grant Recipient
Dr. Shunji Egusa, PhD
Department of Physics and Optical Science the University of North Carolina – Charlotte
Thanks to continued support from the Teddy Kim Foundation, the Leukemia Research Foundation (www.allbloodcancers.org) is proud to fund another New Investigator focused on the causes and cures for acute myeloid leukemia (AML).
2018 & 2017 TKF Grant Recipient
Dr. Jing Li, PhD
Dept of Biology, Shanghai Normal University
Dr. Li’s project funded by the Leukemia Research Foundation is titled The Role of Sirt2 in the Pathogenesis of Acute Myeloid Leukemia (AML). Dr. Li predicts that activation of Sirt2 by inhibiting niche signaling may repress AML progression and enhance the treatment effects of chemotherapy.
2016 TKF Grant Recipient
Dr. Xinyang Zhao, PhD
The University of Alabama - Birmingham, Alabama
The Teddy Kim Foundation (TKF) is proud to announce that it has pledged financial support to the Leukemia Research Foundation (LRF) to further its New Investigator Research Program. As such, funds contributed by TKF in 2016 will provide partial funding of a one year grant to Dr. Xinyang Zhao, PhD at the University of Alabama.